Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
Tsai, Donald E
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. [electronic resource] - Clinical lymphoma Jun 2003 - 56-9 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1526-9655
10.3816/clm.2003.n.015 doi
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antigens, CD--immunology
Antigens, CD20--immunology
Antigens, Differentiation, B-Lymphocyte--immunology
B-Lymphocytes--immunology
Cell Adhesion Molecules
Disease Progression
Humans
Lectins--immunology
Lymphoma, Non-Hodgkin--immunology
Male
Middle Aged
Neoplasm Recurrence, Local--immunology
Radioimmunotherapy--methods
Radiopharmaceuticals
Sialic Acid Binding Ig-like Lectin 2
Treatment Outcome
Yttrium Radioisotopes--therapeutic use
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. [electronic resource] - Clinical lymphoma Jun 2003 - 56-9 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1526-9655
10.3816/clm.2003.n.015 doi
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Antigens, CD--immunology
Antigens, CD20--immunology
Antigens, Differentiation, B-Lymphocyte--immunology
B-Lymphocytes--immunology
Cell Adhesion Molecules
Disease Progression
Humans
Lectins--immunology
Lymphoma, Non-Hodgkin--immunology
Male
Middle Aged
Neoplasm Recurrence, Local--immunology
Radioimmunotherapy--methods
Radiopharmaceuticals
Sialic Acid Binding Ig-like Lectin 2
Treatment Outcome
Yttrium Radioisotopes--therapeutic use